Market Place
Sourcing Support
Pulmatrix & Cullgen Announce Proposed Merger
13 Nov 2024 //
PR NEWSWIRE
Cullgen Announces Additions to Board of Directors and Scientific Advisory Board
16 Jan 2024 //
BUSINESSWIRE
Astellas pays Cullgen $35M upfront to form protein degrader pact
16 Jun 2023 //
FIERCE BIOTECH
Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund
08 May 2023 //
BUSINESSWIRE
Cullgen Announces Chinese NMPA Allowance of Investigational NDA of TRK Degrader
11 Aug 2022 //
BUSINESSWIRE
Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin
17 Jun 2021 //
BUSINESSWIRE
Cullgen Announces Publication by Cullgen Co-Founders in Nature
16 Jun 2021 //
BUSINESSWIRE
Cullgen Appoints Dr. Mark Deeg to Lead Clinical Development
10 Jun 2021 //
BUSINESSWIRE
Cullgen Closes $50 M Series B Investment to Advance Targeted Protein Degraders
25 Feb 2021 //
BUSINESSWIRE
Cullgen Closes $50 Million Series B Investment to Advance Targeted
24 Feb 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.